KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Leases (2019 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Operating Leases for 7 consecutive years, with $145.7 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 10.88% to $145.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.7 million through Dec 2025, up 10.88% year-over-year, with the annual reading at $145.7 million for FY2025, 10.88% up from the prior year.
  • Operating Leases for Q4 2025 was $145.7 million at Bio-Rad Laboratories, down from $155.8 million in the prior quarter.
  • The five-year high for Operating Leases was $212.9 million in Q3 2021, with the low at $126.3 million in Q1 2025.
  • Average Operating Leases over 5 years is $173.3 million, with a median of $172.8 million recorded in 2021.
  • The sharpest move saw Operating Leases soared 40.15% in 2023, then tumbled 36.79% in 2025.
  • Over 5 years, Operating Leases stood at $175.9 million in 2021, then fell by 12.68% to $153.6 million in 2022, then soared by 34.05% to $205.9 million in 2023, then tumbled by 36.18% to $131.4 million in 2024, then rose by 10.88% to $145.7 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $145.7 million, $155.8 million, and $204.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.